晚期基底细胞癌:皮肤科医生需要了解的治疗要点
晚期基底细胞癌的治疗常需超越局部手术切除或放疗。细胞毒性化疗曾用于晚期基底细胞癌,但数据有限且无标准方案。环巴胺的发现促成了维莫德吉和索尼德吉两种Hedgehog抑制剂获批,均用于局部晚期基底细胞癌,维莫德吉还用于转移性基底细胞癌。对Hedgehog抑制剂进展或不耐受者,可使用程序性细胞死亡蛋白1抑制剂西米普利单抗治疗局部晚期或转移性疾病。复杂病例最好通过多学科讨论确定个体化治疗方案。
要点
- 晚期基底细胞癌的治疗常需超越局部手术切除或放疗。
- 维莫德吉和索尼德吉均获批用于局部晚期基底细胞癌,维莫德吉还用于转移性基底细胞癌。
- 对Hedgehog抑制剂进展或不耐受者,西米普利单抗可用于局部晚期或转移性基底细胞癌。
核心结论
- 晚期基底细胞癌的治疗常需超越局部手术切除或放疗,复杂病例最好通过多学科讨论确定个体化方案。
研究设计与样本
- 原文为综述,检索范围未报告。
主要发现
- 细胞毒性化疗曾用于晚期基底细胞癌,但数据有限,未建立标准方案。
- 环巴胺的发现促成了维莫德吉和索尼德吉两种Hedgehog抑制剂获批。
- 维莫德吉和索尼德吉均用于局部晚期基底细胞癌,维莫德吉还用于转移性基底细胞癌。
- 对Hedgehog抑制剂进展或不耐受者,西米普利单抗可用于局部晚期或转移性基底细胞癌。
临床怎么用
- 原文建议复杂局部晚期或转移性基底细胞癌病例通过多学科讨论确定个体化治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of advanced basal cell carcinoma (BCC) often requires therapies beyond local surgical excision or radiation due to the invasiveness of the tumor. Historically, cytotoxic chemotherapy was used to treat advanced BCC, but with limited data, no standard regimens were established. The discovery of cyclopamine, a natural inhibitor in the Hedgehog pathway, led to the development of the 2 currently approved Hedgehog inhibitors, vismodegib and sonidegib. Both agents are indicated for locally advanced BCC, while vismodegib is also indicated for metastatic BCC. In patients who progress on hedgehog inhibitors or cannot tolerate hedgehog inhibitors, the programmed cell death protein 1 inhibitor cemiplimab can be used to treat locally advanced or metastatic disease. Complex cases of locally advanced or metastatic BCC may be best discussed through a multidisciplinary approach in order to determine the optimal treatment approach for the individual patient.
引用
- Wilson M, Johnson RP, Senft SC, et al. Advanced basal cell carcinoma: What dermatologists need to know about treatment. J Am Acad Dermatol. 2022. PMID: 35577406. doi:10.1016/j.jaad.2022.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。